Survival of Patients with Alcohol-Related Liver Disease Cirrhosis-Usefulness of the New Liver Mortality Inpatients Prognostic Score.

IF 3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Vera Matovic Zaric, Ivana Pantic, Sofija Lugonja, Tijana Glisic, Snezana Konjikusic, Iva Lolic, Nevena Baljosevic, Sanja Zgradic, Jasna El Mezeni, Marko Vojnovic, Marija Brankovic, Tamara Milovanovic
{"title":"Survival of Patients with Alcohol-Related Liver Disease Cirrhosis-Usefulness of the New Liver Mortality Inpatients Prognostic Score.","authors":"Vera Matovic Zaric, Ivana Pantic, Sofija Lugonja, Tijana Glisic, Snezana Konjikusic, Iva Lolic, Nevena Baljosevic, Sanja Zgradic, Jasna El Mezeni, Marko Vojnovic, Marija Brankovic, Tamara Milovanovic","doi":"10.3390/diagnostics14222508","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> Alcohol can directly damage the liver, causing steatosis, steatohepatitis, cirrhosis, and hepatocellular cancer. The aim of this study was to examine 28-day survival in hospitalized patients with alcohol-related liver disease (ALD) cirrhosis, as well as to develop and validate a new survival prediction model. <b>Methods:</b> A total of 145 patients with ALD cirrhosis were included; 107 were diagnosed with acute decompensation (AD) and 38 with acute-on-chronic liver failure (ACLF). The new liver mortality inpatients (LIV-IN) score was calculated using the following variables: hepatic encephalopathy (HE), hepatorenal syndrome (HRS), ascites, systemic inflammatory response syndrome (SIRS), community-acquired infection (CAI), and fibrinogen. The diagnostic accuracy of the LIV-IN score was tested, along with the model for end-stage liver disease (MELD), model for end-stage liver disease-sodium (MELD-Na), albumin-bilirubin (ALBI), neutrophil-to-lymphocyte ratio (NLR), chronic liver failure consortium-C acute decompensation (CLIF-C AD), and chronic liver failure consortium-acute-on-chronic liver failure (CLIF-C ACLF). <b>Results:</b> Lethal outcome occurred in 46 (31.7%) patients. The mortality rate was higher in the ACLF group (<i>n</i> = 22, 57.9%) compared to the AD group (<i>n</i> = 24, 22.4%) (<i>p</i> < 0.01). The highest predictive power for short-term mortality was observed for the LIV-IN score (AUC 73.4%, <i>p</i> < 0.01). In patients with AD, the diagnostic accuracy of the CLIF-C AD score was better than for the LIV-IN score (AUC 0.699; <i>p</i> = 0.004, AUC 0.686; <i>p</i> = 0.007, respectively). In patients with ACLF, only the LIV-IN score had statistically significant discriminative power in predicting 28-day survival. <b>Conclusions:</b> The liver mortality inpatients prognostic score is a new, reliable prognostic model in predicting 28-day mortality.</p>","PeriodicalId":11225,"journal":{"name":"Diagnostics","volume":"14 22","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/diagnostics14222508","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: Alcohol can directly damage the liver, causing steatosis, steatohepatitis, cirrhosis, and hepatocellular cancer. The aim of this study was to examine 28-day survival in hospitalized patients with alcohol-related liver disease (ALD) cirrhosis, as well as to develop and validate a new survival prediction model. Methods: A total of 145 patients with ALD cirrhosis were included; 107 were diagnosed with acute decompensation (AD) and 38 with acute-on-chronic liver failure (ACLF). The new liver mortality inpatients (LIV-IN) score was calculated using the following variables: hepatic encephalopathy (HE), hepatorenal syndrome (HRS), ascites, systemic inflammatory response syndrome (SIRS), community-acquired infection (CAI), and fibrinogen. The diagnostic accuracy of the LIV-IN score was tested, along with the model for end-stage liver disease (MELD), model for end-stage liver disease-sodium (MELD-Na), albumin-bilirubin (ALBI), neutrophil-to-lymphocyte ratio (NLR), chronic liver failure consortium-C acute decompensation (CLIF-C AD), and chronic liver failure consortium-acute-on-chronic liver failure (CLIF-C ACLF). Results: Lethal outcome occurred in 46 (31.7%) patients. The mortality rate was higher in the ACLF group (n = 22, 57.9%) compared to the AD group (n = 24, 22.4%) (p < 0.01). The highest predictive power for short-term mortality was observed for the LIV-IN score (AUC 73.4%, p < 0.01). In patients with AD, the diagnostic accuracy of the CLIF-C AD score was better than for the LIV-IN score (AUC 0.699; p = 0.004, AUC 0.686; p = 0.007, respectively). In patients with ACLF, only the LIV-IN score had statistically significant discriminative power in predicting 28-day survival. Conclusions: The liver mortality inpatients prognostic score is a new, reliable prognostic model in predicting 28-day mortality.

酒精相关肝病肝硬化患者的存活率--新肝病死亡率住院患者预后评分的实用性。
背景/目标:酒精会直接损害肝脏,导致脂肪变性、脂肪性肝炎、肝硬化和肝细胞癌。本研究旨在检测酒精相关肝病(ALD)肝硬化住院患者的 28 天存活率,并开发和验证一个新的存活率预测模型。研究方法共纳入145名ALD肝硬化患者,其中107人被诊断为急性失代偿(AD),38人被诊断为急性慢性肝功能衰竭(ACLF)。新的住院患者肝脏死亡率(LIV-IN)评分是通过以下变量计算得出的:肝性脑病(HE)、肝肾综合征(HRS)、腹水、全身炎症反应综合征(SIRS)、社区获得性感染(CAI)和纤维蛋白原。LIV-IN 评分与终末期肝病模型 (MELD)、终末期肝病钠模型 (MELD-Na)、白蛋白胆红素 (ALBI)、中性粒细胞与淋巴细胞比率 (NLR)、慢性肝衰竭联盟-C 急性失代偿 (CLIF-C AD) 和慢性肝衰竭联盟-急性肝衰竭 (CLIF-C ACLF) 一起进行了诊断准确性测试。结果:46例(31.7%)患者出现死亡结果。ACLF 组(22 人,57.9%)的死亡率高于 AD 组(24 人,22.4%)(P < 0.01)。LIV-IN 评分对短期死亡率的预测能力最高(AUC 73.4%,p < 0.01)。在 AD 患者中,CLIF-C AD 评分的诊断准确性优于 LIV-IN 评分(AUC 0.699; p = 0.004,AUC 0.686; p = 0.007)。在 ACLF 患者中,只有 LIV-IN 评分在预测 28 天生存率方面具有显著的统计学鉴别力。结论住院患者肝脏死亡率预后评分是一种新的、可靠的预后模型,可预测 28 天的死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diagnostics
Diagnostics Biochemistry, Genetics and Molecular Biology-Clinical Biochemistry
CiteScore
4.70
自引率
8.30%
发文量
2699
审稿时长
19.64 days
期刊介绍: Diagnostics (ISSN 2075-4418) is an international scholarly open access journal on medical diagnostics. It publishes original research articles, reviews, communications and short notes on the research and development of medical diagnostics. There is no restriction on the length of the papers. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible. Full experimental and/or methodological details must be provided for research articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信